Kopran Q2 FY27 Share Price & Earnings Call Analysis

₹272.66+1.97% today
Market cap
₹1,318 Cr
P/E
33.53
ROE
4.91%
PEG
-17.93
Price to sales
1.66
Debt to equity
0.39
52W high / low
₹291 / ₹108
Sales growth (5Y)
6.74%
EBITDA margin
10.32%
Net profit margin
3.78%
Promoter holding
41.83%
Sales (last year)
₹794 Cr

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Guidance scorecard · Q2 FY27 call

What Kopran's management guided
and where it ranks in Pharmaceuticals & Biotechnology

RevenueQ3 FY25 call

10–20%
  • Kopran Laboratories operates in a fast-growing Indian diagnostic industry expected to grow at a CAGR of 14% over the next 5 years, reaching $25 billion by FY '28 and nearly tripling by 2034.
  • Kopran Labs has shown strong past growth, increasing top line threefold from INR35 crores to INR103 crores in 4 years.
  • The diagnostic segment is expected to participate in this industry growth, with new divisions added recently to drive further revenue.
  • South region operations, started about 3 years ago, hold significant growth potential.
  • Annual addition of 20-25 diagnostic machines is expected, supporting steady volume growth.

2 more points from Kopran's call on revenue

Create a free account to keep reading this call

Full Q3 FY25 analysis

MarginsQ3 FY25 call

Flat

See what Kopran said on margins — free account, 30 seconds.

Full Q3 FY25 analysis

CapexQ3 FY25 call

Planned
  • Kopran Laboratories has a current capital investment approach involving approximately 120 machines deployed on a contracted basis.
  • Annually, they add about 20-25 machines to their reagent rental business.
  • For the current year mentioned, 23-24 machines were added, with a possibility of 1-2 more before year-end.
  • The expected annual investment in machines is around INR 7 to 8 crores.
  • All these capital expenditures are funded through internal accruals, supported by a substantial cash reserve.

2 more points from Kopran's call on capex

Create a free account to keep reading this call

Full Q3 FY25 analysis

FundraisingQ3 FY25 call

None planned

See what Kopran said on fundraising — free account, 30 seconds.

Full Q3 FY25 analysis

Order bookQ3 FY25 call

  • Kopran Laboratories has close to 120 machines deployed across India on a contracted basis.
  • Each machine is part of a long-term contract averaging around 5 to 5.5 years.
  • The company typically adds 20 to 25 new machines annually; 23-24 machines were added in the current year.
  • These contracts ensure recurrent purchase of consumables, forming an annuity-like revenue stream.
  • Kopran anticipates continuing this orderbook growth annually, funded through internal accruals.
  • They maintain warehousing and cold chain logistics to support ongoing orders.

2 more points from Kopran's call on the order book

Create a free account to keep reading this call

Full Q3 FY25 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. 1
  3. 3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Kopran latest results (Sep 2026)

Revenue

₹211 Cr

+79.17% YoY

Net profit

₹4 Cr

Operating margin

7.29%

EPS

₹0.91

What management said on the call →

Kopran shareholding (Sep 2026)

Promoters

41.83%

−2.60 pp QoQ

FIIs

0.91%

+0.40 pp QoQ

DIIs

0.00%

unchanged QoQ

Public

57.26%

+2.20 pp QoQ

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹3,142 Cr34.2
240%+Up 2%+₹489 Cr16.7
340%+Up 0–2%₹234 Cr17.8
440%+Flat₹18,464 Cr1614.0
540%+Flat₹9,050 Cr34.8
640%+Flat₹4,493 Cr—

Financials of Kopran

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Kopran

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +44.49%44.49%44.49%44.49%44.45%44.42%44.43%44.43%44.43%44.43%44.43%41.83%
FIIs +0.48%0.84%0.68%1.31%0.86%1.11%0.76%0.60%0.36%0.57%0.51%0.91%
DIIs +0.14%1.20%0.14%0.22%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public +54.88%53.47%54.68%53.98%54.68%54.45%54.81%54.99%55.21%55.01%55.06%57.26%
No. of Shareholders51,63650,85051,49257,15460,56058,65260,19462,22260,88658,63956,92552,924

Financials of Kopran

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +152.59158.92186.08139.44151.56166.24172.36135.22117.91194.28234.02153.99211.26
YoY Sales growth+30.45%+0.58%+24.99%+19.18%-0.68%+4.61%-7.37%-3.03%-22.20%+16.87%+35.77%+13.88%+79.17%
Expenses +129.76135.34164.39121.28136.83146.39155.27121.09123.19176.52201.08138.18195.85
Operating Profit22.8323.5821.6918.1614.7319.8517.0914.13-5.2817.7632.9415.8115.41
OPM %14.96%14.84%11.66%13.02%9.72%11.94%9.92%10.45%-4.48%9.14%14.08%10.27%7.29%
Other Income +0.132.439.672.631.000.173.262.560.030.070.092.050.62
Interest1.942.242.592.182.232.162.772.542.092.673.173.284.25
Depreciation2.773.273.593.873.854.003.874.264.284.424.525.775.89
Profit before tax18.2520.5025.1814.749.6513.8613.719.89-11.6210.7425.348.815.89
Tax %24.55%23.02%26.01%24.69%23.42%24.96%29.39%24.67%-14.63%13.04%25.57%23.84%25.47%
Net Profit +13.7715.7918.6211.107.3810.409.687.45-9.929.3418.876.704.39
EPS in Rs2.863.283.862.301.532.162.011.54-2.061.943.911.390.91

Financials of Kopran

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +326296310313358360492478551615630681794
Sales growth+8%-9%+5%+1%+14%+0%+37%-3%+15%+12%+2%+8%+34%
Expenses +294266274283312313410390499540557619712
Operating Profit31303631464782875274736282
OPM %10%10%12%10%13%13%17%18%9%12%12%9%10%
Other Income +-4811193-01811315403
Interest131314999656991013
Depreciation1088991010111313161721
Profit before tax-39112523322883823668523451
Tax %0%0%20%10%24%26%26%25%24%25%26%25%
Net Profit +-39112020242162612751392639
EPS in Rs-9.522.484.604.745.554.8614.2412.665.6510.577.995.338.15
Dividend Payout %0%0%0%0%0%0%21%24%53%28%38%56%

Financials of Kopran

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital41434343434343484848484848
Reserves495781101125146202378391443470482480
Borrowings +86809589978866757599148153208
Other Liabilities +998478828592128110135153178225227
Total Liabilities275264298315351370439611650743844908964
Fixed Assets +102101104104113111112151165182208346378
CWIP136102430433670971132512
Investments0000000000000
Other Assets +172160187201214229284425415465522537574
Total Assets275264298315351370439611650743844908964

Financials of Kopran

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +46291626253160-3334434267
Cash from Investing Activity +-10-9-18-11-25-13-25-84-13-44-56-65
Cash from Financing Activity +-37-192-15-1-18-35123-20126-21
Net Cash Flow-00-0-0-00052111-19
Free Cash Flow3518-014-61743-76-27-13-17-0
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit147%95%47%94%63%82%93%-17%90%77%76%117%

Financials of Kopran

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9170867588948997108126125141
Inventory Days78119122138129154121202133126153137
Days Payable1191159511890951048489103108131
Cash Conversion Cycle507411396127153106215152149170146
Working Capital Days934436070798115813913111391
ROCE %14%14%19%14%16%14%30%21%8%14%10%7%

Guidance history

How Kopran's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q3 FY25 call →10–20%FlatPlannedNone planned—
Q3 FY25 call →10–20%Up 2%+PlannedNone planned—
Q2 FY25 call →10–20%FlatPlanned——
Q1 FY25 call →20–40%Up 2%+Planned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

46out of 100

Momentum score · price trend

46 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,947 stocks
Last 12 months+95.7%93%
Last 6 months+58.3%91%
Last 3 months+35.3%96%

The price is 21.4% below its all-time high of ₹346.8 (13 Sept 2024). Stocks more than 20% below their peak have their score halved, so 93 became 46.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Kopran: 0.4 × 93 + 0.4 × 91 + 0.2 × 96 = 93, halved to 46 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Kopran: frequently asked questions

What is Kopran share price today?

Kopran last traded at ₹272.66, with a market capitalisation of ₹1,318 Cr and a P/E ratio of 33.5.

What were Kopran's latest quarterly results?

For the quarter ended Sep 2026, Kopran reported revenue of ₹211 Cr (+79.17% year on year) and net profit of ₹4 Cr, with an operating margin of 7.29%.

Is Kopran's profit growing?

Net profit was ₹4 Cr in Sep 2026 against ₹-10 Cr in Sep 2025.

What is Kopran's EPS?

Kopran's earnings per share for the quarter ended Sep 2026 was ₹0.91.

What is the promoter holding in Kopran?

Promoters held 41.83% of Kopran in Sep 2026 (−2.60 pp versus Jun 2026).

How much do FIIs and DIIs hold in Kopran?

In Sep 2026, foreign institutional investors held 0.91% and domestic institutions (including mutual funds) held 0.00% of Kopran.

What is Kopran's ROE and ROCE?

Kopran's return on equity is 4.91% and its return on capital employed is 6.65%.

Does Kopran pay a dividend?

Yes. Kopran's dividend yield is 1.15% at the current price. The full payout history is on the Kopran dividends page.

Which sector does Kopran belong to?

Kopran is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.

What did Kopran's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Kopran's management.

How does Arthneeti AI analyse Kopran?

Arthneeti reads Kopran's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem